Sensus Healthcare, Inc. launched the SRT-100™ in China for the treatment and prevention of keloids with Chindex Medical Limited.
Sensus also announced the extension of its exclusive distribution agreement with Chindex Medical, a joint venture between Fosun Pharma and Chindex International, Inc., through 2020.
SRT-100 launch activities were organized by Chindex Medical in conjunction with the International Congress of Dermatologic & Aesthetic Surgery International League (DASIL) in Shanghai, followed by additional launch activities in Beijing.
In July 2017, the SRT-100 received clearance from the China Food and Drug Administration for the treatment and prevention of keloids. Chindex Medical is focused on preventing and treating keloids associated with Cesarean sections. and Sensus has developed a special applicator for use with the SRT-100 for this indication. The SRT-100 previously received clearance in China for the treatment of non-melanoma skin cancer, and has been marketed by Chindex Medical for that indication since 2015.